טוען...
Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013
Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here we report the preclinical development of the proposed biosimilar rituximab (GP2013). Post-translational modifications and bioactivities of GP2013 versus originator rituximab were e...
שמור ב:
| Main Authors: | , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Informa Healthcare
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4133973/ https://ncbi.nlm.nih.gov/pubmed/24024472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.843090 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|